QTTB
Strong BuyPremium GrowerAI neutralQ32 Bio Inc. · Healthcare · United States · $258M cap · $8.0M/day traded
$8.45 -2.3% · close 26 Oct · scored 27 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 27 Oct 2026, MoatMap's StockRank for Q32 Bio Inc. (QTTB) is 88/100, ranked against 24,000+ stocks in 35 markets (Quality 87, Value 44, Momentum 57, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Q32 Bio is a clinical-stage biotech developing bempikibart for alopecia areata and other autoimmune diseases. It raised about $200 million in July 2026, which funds the programme for now, and results from Part B of its SIGNAL-AA trial are due at a major dermatology congress. The company has no product revenue, so its value rests almost entirely on trial data and eventual approval. That makes it a binary scientific outcome rather than a business with measurable economics.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT Q32 BIO INC.
Read
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.7M | -6.7M | 0 | 53.7M | 100.7% | 53.7M | 0.3M | 0.8M | -87.5% |
| EPS | -1.44 | -1.81 | -2.10 | 1.05 | — | — | — | — | — |
| Shares | 29.7M | 29.7M | 29.7M | 29.7M | 0.0% | 29.8M | — | — | — |
| Debt | 44.7M | 50.8M | 18.9M | 15.3M | -30.0% | 5.3M | — | — | — |
| Equity | -130.7M | -182.9M | 5.7M | 42.0M | 640.3% | — | — | — | — |
| Op CF | -11.0M | -18.7M | -67.7M | -33.5M | — | -19.8M | — | — | — |
| Inv CF | -2.5M | -5.0K | 19.9M | 7.0M | — | — | — | — | — |
| Fin CF | 30.1M | 0.4M | 95.1M | -3.1M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 99% of stocks we rank over the past year (171% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QTTB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc.(you) | $258M | 88 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 98 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $387M | 94 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $583M | 90 | Strong Buy |
| AGEN | Agenus Inc. | $286M | 67 | Buy |
| ORMP | Oramed Pharmaceuticals Inc. | $172M | 73 | Buy |
| PBYI | Puma Biotechnology, Inc. | $569M | 97 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $644M | 81 | Strong Buy |
| CRMD | CorMedix Inc. | $612M | 98 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.